Rezo Therapeutics Appoints Cristiana Guiducci, Ph.D., as Chief Scientific Officer
2024年7月18日 - 9:00PM
ビジネスワイヤ(英語)
Rezo Therapeutics, a biotechnology company pioneering the
integrated mapping of disease networks for precision therapeutics,
today announced the appointment of Cristiana Guiducci, Ph.D., as
chief scientific officer. Dr. Guiducci previously served as senior
vice president of immunology and oncology research of Nurix
Therapeutics and has nearly 20 years of experience in oncology and
immunology drug discovery research.
“Cristiana brings deep scientific experience in drug discovery
and has important expertise in building foundational research
teams, identifying drug candidates and laying the groundwork for
clinical advancement,” said Nevan Krogan, Ph.D., president and
co-founder of Rezo Therapeutics. “Cristiana’s appointment to CSO is
an instrumental step for Rezo as we continue to expand our
scientific acumen and work towards comprehensive mapping of
molecular disease networks to inform the development of a new wave
of therapies.”
“After spending my career embedded in advancing research across
oncology and autoimmune diseases, I’m looking forward to joining
Rezo and contributing to its integrated approach to drug
discovery,” said Dr. Guiducci. “The Rezo platform, which integrates
AI and machine learning, has the potential to serve an important
role in drug development by uniting multiple technologies and tools
to increase the understanding of disease networks, novel targets,
and therapies. In joining Rezo, I’m thrilled to be part of the
cutting edge of drug development.”
Prior to Nurix Therapeutics, Dr. Guiducci spent more than
thirteen years at Dynavax Technologies, in which she directed
discovery and characterization of drug candidates for both oncology
and autoimmune diseases at different points. She eventually served
as vice president of oncology research, in which she was
responsible for directing all foundational research for the Dynavax
immuno-oncology assets. Dr. Guiducci earned bachelor’s and master’s
degrees in molecular biology from University of Rome, Italy, a
Ph.D. in immunology from the Open University of London, UK, and
completed post-doctoral training at National Tumor Institute in
Milan, Italy.
About Rezo Therapeutics
Rezo is pursuing an integrated approach to drug discovery that
leverages the multiple technologies and tools needed to bring
disease networks into focus, pinpointing novel targets and
therapies with more clarity. Rezo’s Sequence to Systems to Drugs
platform integrates proteomics, genetics, structural biology,
chemistry, artificial intelligence and machine learning to create
maps of molecular disease networks. Based on the work of the
founding team at the Quantitative Biosciences Institute (QBI) at
the University of California, San Francisco (UCSF), the company’s
mission is to break the mold in traditional drug development, which
is slow and often siloed. The company’s initial focus is in
oncology, with plans to explore additional therapeutic areas
through collaborations and partnerships. To learn more, visit the
company’s website at www.rezotx.com or its LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717489135/en/
Katie Engleman 1AB katie@1abmedia.com